Drug intelligence / Profile preview

lutetium-177-CTR-FAPI

Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

lutetium-177-CTR-FAPI (also known as 177Lu-BRP-010030) is an innovative, covalent-engineered radiopharmaceutical therapy (RLT) developed by Boomray Pharmaceuticals in collaboration with Peking University. It consists of a fibroblast activation protein inhibitor (FAPI) conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). Unlike conventional FAPI ligands that bind reversibly, lutetium-177-CTR-FAPI utilizes a proprietary Covalent Targeted Radioligand (CTR) technology platform with a sulfur(VI)-fluoride exchange (SuFEx) chemical warhead. This allows the molecule to form an irreversible covalent bond with the tyrosine residues of fibroblast activation protein (FAP) overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment. This covalent anchoring results in significantly higher tumor uptake, prolonged intratumoral retention, and enhanced therapeutic efficacy with manageable systemic toxicity. The drug is currently in Phase 1 clinical development for the treatment of FAP-expressing advanced solid tumors, including thyroid cancer, breast cancer, sarcoma, and gastrointestinal malignancies.

Other names
177Lu-CTR-FAPI177Lu-DOTA-mFS-FAPI-04lutetium Lu 177 CTR-FAPI
02

Identity

Drug type
Radiopharmaceuticals
Originator
Peking University
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesBeta-minus EmittersGamma Emitters
Synonyms and codes
177Lu-BRP-010177Lu-BRP-010030
03

Pharmacology

Targets

Route
Intravenous
04

Development

IndicationHighest phaseStatus
breast cancer and precursor lesionsIn developmentActive
gastrointestinal cancers and precursor lesionsIn developmentActive
liver and biliary tract cancers and premalignant lesionsIn developmentActive
soft-tissue sarcomasIn developmentActive
thyroid cancer and precursor lesionsIn developmentActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
95
Drugs in the lead indication
1,053

Lead indication: breast cancer and precursor lesions

Most advanced in the lead indication

  1. cyclophosphamideApproved
  2. epirubicinApproved
  3. eribulinApproved
  4. fludeoxyglucose f 18Approved
  5. fluorouracilApproved

Beyond the preview

Go deeper on lutetium-177-CTR-FAPI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium-177-CTR-FAPI.

Work on lutetium-177-CTR-FAPI? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call